| 000 | 01761 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250513154626.0 | ||
| 264 | 0 | _c19990212 | |
| 008 | 199902s 0 0 eng d | ||
| 022 | _a1078-0432 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMiller, A A | |
| 245 | 0 | 0 |
_aPharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062). _h[electronic resource] |
| 260 |
_bClinical cancer research : an official journal of the American Association for Cancer Research _cMay 1997 |
||
| 300 |
_a719-25 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xpharmacokinetics |
| 650 | 0 | 4 |
_aBone Marrow _xpathology |
| 650 | 0 | 4 |
_aCarcinoma, Small Cell _xdrug therapy |
| 650 | 0 | 4 |
_aCisplatin _xadministration & dosage |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 |
_aEtoposide _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInfusions, Intravenous |
| 650 | 0 | 4 |
_aLung Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 | _aRegression Analysis |
| 650 | 0 | 4 | _aTime Factors |
| 700 | 1 | _aRosner, G L | |
| 700 | 1 | _aRatain, M J | |
| 700 | 1 | _aHollis, D R | |
| 700 | 1 | _aGreen, M R | |
| 700 | 1 | _aSchilsky, R L | |
| 773 | 0 |
_tClinical cancer research : an official journal of the American Association for Cancer Research _gvol. 3 _gno. 5 _gp. 719-25 |
|
| 999 |
_c9779958 _d9779958 |
||